注射用头孢哌酮钠舒巴坦钠治疗感染性疾病的临床效果及安全性分析

Analysis of clinical effect and safety of cefoperazone sodium and sulbactam sodium for injection in the treatment of infectious diseases

目的研究注射用头孢哌酮钠舒巴坦钠治疗感染性疾病的临床效果及不良反应发生情况。方法112例感染性疾病患者,根据掷硬币法分为对照组和观察组,每组56例。对照组采用头孢他啶治疗,观察组采用注射用头孢哌酮钠舒巴坦钠治疗。比较两组治疗前后炎症细胞因子[白细胞计数(WBC),C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]水平、临床症状消失时间、致病菌清除率、临床疗效、用药安全性、用药合理性。结果治疗后,两组患者的WBC、CRP、IL-6、IL-8水平均低于本组治疗前,且观察组患者的WBC(3.75±0.68)×10^(9)/L、CRP(2.09±0.50)mg/L、IL-6(61.70±7.74)pg/ml、IL-8(160.83±6.92)pg/ml均低于对照组的(7.05±1.96)×10^(9)/L、(4.95±0.86)mg/L、(84.91±12.57)pg/ml、(207.56±12.31)pg/ml,差异具有统计学意义(P<0.05)。观察组患者的退热时间、咳嗽咳痰消失时间、胸闷气短消失时间分别为(1.92±0.43)、(2.67±0.54)、(2.40±0.56)d,明显短于对照组的(3.09±0.70)、(5.12±1.03)、(4.87±0.96)d,差异具有统计学意义(P<0.05)。观察组患者致病菌清除率为91.07%,高于对照组的75.00%,差异具有统计学意义(P<0.05)。观察患者总有效率为96.43%,明显高于对照组的78.57%,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为5.36%,低于对照组的17.86%,差异具有统计学意义(P<0.05)。观察组患者用药不合理发生率为3.57%,低于对照组的16.07%,差异具有统计学意义(P<0.05)。结论注射用头孢哌酮钠舒巴坦钠具有较高的抗感染效果,能够有效减轻感染性疾病患者的炎症反应,改善其临床症状,且用药合理性以及安全性较高,值得推广应用。

Objective To study the clinical effect and occurrence of adverse reactions of cefoperazone sodium and sulbactam sodium for injection in the treatment of infectious diseases.Methods A total of 112 patients with infectious diseases were divided into control group and observation group according to the coin-tossing method,with 56 cases in each group.The control group was treated with ceftazidime,and the observation group was treated with cefoperazone sodium and sulbactam sodium for injection.Both groups were compared in terms of levels of inflammatory cytokines[white blood cell count(WBC),C-reactive protein(CRP),interleukin-6(IL-6),interleukin-8(IL-8)]before and after treatment,disappearance time of clinical symptoms,clearance rate of pathogenic bacteria,clinical efficacy,medication safety,and drug rationality.Results After treatment,the levels of WBC,CRP,IL-6 and IL-8 in the two groups were lower than those before treatment in this group;the WBC(3.75±0.68)×10^(9)/L,CRP(2.09±0.50)mg/L,IL-6(61.70±7.74)pg/ml and IL-8(160.83±6.92)pg/ml in the observation group were lower than(7.05±1.96)×10^(9)/L,(4.95±0.86)mg/L,(84.91±12.57)pg/ml and(207.56±12.31)pg/ml in the control group;the differences were all statistically significant(P<0.05).The antipyretic time,disappearance of cough and expectoration,and disappearance of chest tightness and shortness of breath in the observation group were(1.92±0.43),(2.67±0.54),and(2.40±0.56)d,which were significantly shorter than(3.09±0.70),(5.12±1.03),and(4.87±0.96)d in the control group,and the differences were all statistically significant(P<0.05).The clearance rate of pathogenic bacteria in the observation group was 91.07%,which was higher than 75.00%in the control group,and the difference was statistically significant(P<0.05).The total effective rate of the observation group was 96.43%,which was significantly higher than 78.57%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 5.36%,which was lower than 17.86%in the control group,and the difference was statistically significant(P<0.05).The incidence of irrational drug use in the observation group was 3.57%,which was lower than 16.07%in the control group,and the difference was statistically significant(P<0.05).Conclusion Cefoperazone sodium and sulbactam sodium for injection has a high anti-infective effect.It can effectively reduce the inflammatory response of patients with infectious diseases,improve their clinical symptoms,and the medication is reasonable and safe,which is worthy of popularization and application.